Congenital Adrenal Hyperplasia Medical Services in China

Congenital Adrenal Hyperplasia (CAH) is a group of inherited autosomal recessive disorders characterized by enzymatic defects in the steroidogenesis pathway within the adrenal cortex. The most common form—accounting for over 90% of cases—is 21-hydroxylase deficiency, caused by mutations in the CYP21A2 gene. This defect impairs cortisol and often aldosterone synthesis, leading to compensatory adrenocorticotropic hormone (ACTH) overproduction, adrenal hyperplasia, and excessive accumulation of precursor steroids—particularly androgens. As a result, affected individuals may present with prenatal virilization in females (e.g., ambiguous genitalia), postnatal rapid growth and premature epiphyseal fusion, hypertension or salt-wasting crises (in severe classic forms), hirsutism, acne, menstrual irregularities, and infertility. Nonclassic CAH, a milder variant, often manifests later in childhood or adulthood with symptoms resembling polycystic ovary syndrome (PCOS) or idiopathic hirsutism. Epidemiologically, classic CAH occurs in approximately 1 in 10,000–15,000 live births globally, with higher prevalence in certain populations (e.g., 1 in 280 in the Yupik Eskimo population). Carrier frequency is estimated at 1 in 50–100 in most ethnic groups. Risk factors include consanguinity and family history; newborn screening programs—now implemented in all U.S. states and many high-income countries—enable early diagnosis and life-saving intervention. Without timely and lifelong management, CAH significantly impacts quality of life: children face psychosocial challenges related to genital surgery, short stature, and early puberty; adults report higher rates of anxiety, depression, sexual dysfunction, and reduced fertility. Chronic glucocorticoid replacement carries risks of obesity, insulin resistance, osteoporosis, and cardiovascular morbidity—underscoring the need for individualized dosing and multidisciplinary care involving endocrinologists, genetic counselors, pediatric urologists (when indicated), and mental health professionals. Lifelong adherence to medication, regular monitoring of hormone levels (17-OHP, androstenedione, renin), growth velocity, bone age, and metabolic parameters is essential to optimize outcomes and minimize complications.

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive disorders characterized by enzymatic defects in the steroidogenesis pathway within the adrenal cortex, leading to impaired cortisol (and often aldosterone) synthesis and compensatory adrenal hyperplasia. The most common cause—accounting for over 90% of cases—is a pathogenic variant in the CYP21A2 gene, which encodes 21-hydroxylase. This enzyme catalyzes the conversion of 17-hydroxyprogesterone to 11-deoxycortisol (a cortisol precursor) and progesterone to deoxycorticosterone (an aldosterone precursor). Deficiency results in cortisol deficiency, elevated ACTH due to loss of negative feedback, and adrenal hyperplasia with accumulation and shunting of precursors into androgen biosynthesis pathways—causing prenatal virilization in females and postnatal androgen excess in both sexes. Less common enzymatic defects include 11β-hydroxylase deficiency (CYP11B1), 3β-hydroxysteroid dehydrogenase type 2 deficiency (HSD3B2), steroidogenic acute regulatory protein (StAR) deficiency (lipoid CAH), cytochrome P450 oxidoreductase (POR) deficiency, and rare defects in CYP17A1 (17α-hydroxylase/17,20-lyase) or HSD17B3. Each defect produces a distinct biochemical and clinical phenotype: for example, 11β-hydroxylase deficiency causes hypertension and hypokalemia due to mineralocorticoid excess (11-deoxycortisol and deoxycorticosterone), whereas StAR deficiency leads to profound glucocorticoid and mineralocorticoid insufficiency with severe salt-wasting and absent sex steroid production.

Genetic factors are central to CAH etiology. All forms follow autosomal recessive inheritance; affected individuals inherit two pathogenic alleles—one from each asymptomatic carrier parent. Carrier frequency varies by population: ~1:50–1:60 in Caucasians for CYP21A2 variants, but as high as 1:27 in Ashkenazi Jewish and 1:30 in Hispanic populations. Over 1,000 CYP21A2 variants have been identified—including large gene deletions, chimeric genes (CYP21A1P/CYP21A2), and missense, nonsense, and splice-site mutations—with genotype-phenotype correlations guiding severity prediction (e.g., null alleles typically associate with classic salt-wasting CAH; p.Val281Leu with nonclassic CAH). Consanguinity significantly increases risk, particularly in communities with high carrier prevalence. De novo mutations are exceedingly rare and not considered clinically relevant.

Triggers are not causal but unmask or exacerbate disease manifestations. Acute adrenal crisis—a life-threatening emergency—can be precipitated by physiological stressors including infection, trauma, surgery, or intercurrent illness, especially in undiagnosed or undertreated patients. In classic CAH, abrupt glucocorticoid withdrawal or inadequate stress-dose hydrocortisone coverage during illness may trigger hypotension, hyponatremia, hyperkalemia, hypoglycemia, and shock. In nonclassic CAH, symptoms such as hirsutism, oligomenorrhea, infertility, or premature pubarche may become apparent during puberty or adulthood under hormonal fluctuations, weight gain, or insulin resistance—conditions that amplify adrenal androgen output via increased ACTH sensitivity and intra-adrenal IGF-1 signaling.

Environmental factors do not cause CAH but modulate phenotypic expression and long-term outcomes. Chronic glucocorticoid overtreatment—often used to suppress androgen excess—may contribute to iatrogenic Cushing syndrome, obesity, insulin resistance, osteopenia, and growth impairment in children. Conversely, suboptimal dosing permits persistent hyperandrogenism, accelerating epiphyseal fusion and compromising adult height. Nutritional status influences metabolic comorbidities: obesity amplifies insulin resistance and hyperinsulinemia, further stimulating adrenal androgen secretion. Exposure to endocrine-disrupting chemicals (e.g., phthalates, bisphenol A) has not been causally linked to CAH but may theoretically interfere with steroidogenic enzymes or ACTH receptor signaling in susceptible individuals—though robust epidemiological evidence is lacking. Maternal factors—including gestational diabetes or obesity—do not induce CAH but may confound prenatal diagnosis or complicate management of affected fetuses. Importantly, no environmental exposure can induce the genetic defect underlying CAH; however, prenatal dexamethasone treatment (administered before genetic confirmation to prevent virilization in at-risk female fetuses) remains controversial due to uncertain neurodevelopmental safety and ethical concerns regarding treatment of unaffected fetuses.

In summary, CAH arises exclusively from inherited enzymatic defects in adrenal steroidogenesis, with 21-hydroxylase deficiency dominating epidemiologically. Genetic predisposition is necessary and sufficient for disease development; environmental and physiological triggers influence clinical presentation and complications but do not initiate the disorder. Comprehensive care requires lifelong multidisciplinary monitoring—including endocrinology, genetics, and, when indicated, reproductive medicine—to balance hormone replacement, mitigate androgen excess, prevent adrenal crises, and address psychosocial and metabolic sequelae.

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive disorders caused by enzymatic defects in cortisol biosynthesis within the adrenal cortex, most commonly due to 21-hydroxylase deficiency (accounting for >90% of cases). The clinical presentation varies widely depending on the severity of the enzymatic defect, age at onset, and sex of the affected individual. CAH is classified into classic (severe) and nonclassic (mild) forms; classic CAH further subdivides into salt-wasting and simple virilizing variants.

Early symptoms typically manifest in the neonatal period or infancy in classic CAH. In salt-wasting CAH—characterized by combined cortisol and aldosterone deficiency—neonates may present with life-threatening adrenal crisis between days 5–14 of life. Key early signs include poor feeding, vomiting, lethargy, hypotonia, dehydration, hypoglycemia, hyponatremia, hyperkalemia, metabolic acidosis, and hypovolemic shock. Females with classic CAH often exhibit ambiguous genitalia at birth due to prenatal androgen excess: clitoromegaly, labial fusion, and urogenital sinus formation—collectively termed Prader stage I–V virilization. Male infants, however, usually have normal-appearing external genitalia at birth but may display penile enlargement and hyperpigmentation of the scrotum or areolae secondary to elevated ACTH-driven melanocyte-stimulating hormone (MSH) secretion. Nonclassic CAH typically remains asymptomatic in infancy and childhood; symptoms emerge in late childhood, adolescence, or adulthood, often triggered by puberty or stress.

Typical symptoms reflect chronic glucocorticoid insufficiency and/or androgen excess. In children with classic CAH, rapid linear growth acceleration and advanced bone age occur early, followed by premature epiphyseal fusion and ultimately short adult stature. Precocious pubarche (pubic hair before age 8 in girls, age 9 in boys), acne, oily skin, hirsutism, oligomenorrhea or amenorrhea, and infertility are hallmark features of hyperandrogenism. Males may develop testicular adrenal rest tumors (TARTs), which can impair spermatogenesis. In females, chronic anovulation and polycystic ovarian morphology are common. Adults with untreated or poorly controlled CAH frequently report fatigue, exercise intolerance, orthostatic dizziness, and recurrent abdominal pain—signs of relative adrenal insufficiency. Hypertension may occur in patients with 11β-hydroxylase or 17α-hydroxylase deficiencies due to mineralocorticoid excess (e.g., deoxycorticosterone accumulation) or cortisol deficiency-induced renin suppression, respectively.

Accompanying symptoms include hyperpigmentation of skin creases, gums, and mucosal surfaces due to chronically elevated ACTH stimulating melanocortin-1 receptors. Patients often exhibit irritability, poor weight gain, and delayed developmental milestones secondary to chronic illness or recurrent hypoglycemia. Psychological comorbidities—including anxiety, depression, reduced health-related quality of life, and body image concerns—are prevalent, particularly among adolescents and women with genital ambiguity or hirsutism. Sleep disturbances and decreased libido may also occur. In nonclassic CAH, symptoms are subtler and often misattributed: adolescent girls may present with idiopathic hirsutism or menstrual irregularities; males may experience premature balding or oligospermia; both sexes may report infertility or subfertility.

Complications arise from both disease pathophysiology and long-term therapeutic interventions. Acute adrenal crisis—precipitated by infection, trauma, or surgical stress—remains the most immediate life-threatening complication, presenting with profound hypotension, shock, and coma. Chronic complications include short stature, obesity, insulin resistance, dyslipidemia, and increased cardiovascular risk. Glucocorticoid overtreatment contributes to iatrogenic Cushing syndrome: central adiposity, striae, osteopenia/osteoporosis, vertebral compression fractures, cataracts, glaucoma, and impaired immune surveillance. Underreplacement leads to persistent hyperandrogenism and its sequelae, including endometrial hyperplasia and increased risk of endometrial carcinoma in unopposed estrogen states. TARTs may cause testicular enlargement, pain, or obstructive azoospermia. In females with severe genital ambiguity, psychosexual distress, gender dysphoria, and sexual dysfunction are well-documented. Neonatal salt-wasting crises carry significant mortality if undiagnosed or mismanaged.

Diagnosis relies on biochemical and genetic evaluation. First-line screening in newborns involves measuring 17-hydroxyprogesterone (17-OHP) in dried blood spots; markedly elevated levels (>10,000 ng/dL) strongly suggest classic 21-hydroxylase deficiency. Confirmatory testing includes serum 17-OHP, androstenedione, testosterone, cortisol, ACTH, renin, aldosterone, and electrolytes. ACTH stimulation testing (cosyntropin test) helps differentiate classic from nonclassic forms and assess residual enzyme activity. Basal and stimulated 17-OHP >1000 ng/dL post-ACTH suggests nonclassic CAH. Molecular genetic analysis of the CYP21A2 gene identifies pathogenic variants and enables carrier testing and prenatal diagnosis. Prenatal diagnosis via chorionic villus sampling or amniocentesis is available for at-risk pregnancies. Imaging—pelvic ultrasound in females to evaluate internal genitalia, testicular ultrasound to detect TARTs, and adrenal CT/MRI in atypical presentations—supports clinical correlation.

Differential diagnosis must exclude other causes of hyperandrogenism, adrenal insufficiency, or ambiguous genitalia. Conditions mimicking classic CAH include adrenal hemorrhage, sepsis-induced adrenal insufficiency, mitochondrial disorders (e.g., Pearson syndrome), and other inborn errors of metabolism (e.g., Smith-Lemli-Opitz syndrome). For ambiguous genitalia, differentials include 3β-hydroxysteroid dehydrogenase deficiency, 11β-hydroxylase deficiency, aromatase deficiency, androgen insensitivity syndrome (AIS), and gonadal dysgenesis. Nonclassic CAH must be distinguished from polycystic ovary syndrome (PCOS), idiopathic hirsutism, hyperprolactinemia, Cushing disease, and ovarian or adrenal tumors. Elevated 17-OHP without clinical hyperandrogenism warrants caution: false positives occur with prematurity, critical illness, or assay interference. Conversely, mild 21-hydroxylase deficiency may yield borderline 17-OHP elevations, necessitating dynamic testing. Distinguishing CAH from PCOS requires assessment of basal and ACTH-stimulated 17-OHP, as PCOS patients show normal responses. Tumoral androgen excess typically presents with rapidly progressive virilization and disproportionately elevated testosterone or DHEA-S, unlike the gradual progression seen in CAH.

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive disorders caused by enzymatic defects in cortisol biosynthesis within the adrenal cortex, most commonly due to 21-hydroxylase deficiency (90–95% of cases). These defects lead to cortisol and often aldosterone deficiency, coupled with excessive androgen production. Clinical manifestations range from life-threatening salt-wasting crises in infancy to milder, non-classic forms presenting with precocious puberty, hirsutism, oligomenorrhea, or infertility in adolescence and adulthood. Management requires lifelong, multidisciplinary endocrine care focused on hormone replacement, androgen suppression, growth optimization, and psychosocial support.

Conservative treatment constitutes the cornerstone of CAH management and is initiated immediately upon diagnosis—often prenatally via maternal dexamethasone administration in high-risk pregnancies (though this remains investigational and ethically nuanced) or postnatally following newborn screening. The primary goals are to normalize glucocorticoid and mineralocorticoid levels, suppress pathological ACTH-driven adrenal hyperplasia and androgen overproduction, prevent adrenal crisis, and support normal linear growth and pubertal development. Conservative strategies include meticulous dose titration based on clinical assessment (e.g., height velocity, bone age advancement, Tanner staging), biochemical monitoring (early-morning serum 17-hydroxyprogesterone, androstenedione, renin activity, electrolytes, cortisol), and regular surveillance for comorbidities such as obesity, insulin resistance, hypertension, and reduced bone mineral density. Lifestyle interventions—including structured physical activity, nutritional counseling to mitigate glucocorticoid-induced weight gain and metabolic syndrome, and psychological evaluation—are integral components. In non-classic CAH, conservative management may involve observation alone in asymptomatic individuals or low-dose glucocorticoids only during periods of stress or when symptoms (e.g., acne, anovulation) emerge.

Pharmacotherapy is central to CAH treatment. Glucocorticoid replacement is mandatory in classic CAH: hydrocortisone is preferred in infants and children due to its short half-life, allowing physiological diurnal dosing (typically two-thirds in the morning, one-third in early afternoon) and minimizing growth suppression. Adults may transition to longer-acting agents like prednisolone or dexamethasone, though dexamethasone carries higher risks of iatrogenic Cushing’s syndrome and osteoporosis and is avoided in pediatric patients unless strictly indicated. Mineralocorticoid replacement with fludrocortisone acetate (0.05–0.2 mg/day) plus supplemental sodium chloride (1–2 g/day in infancy) is essential in salt-wasting forms to maintain intravascular volume, normalize plasma renin activity, and prevent hyponatremia and hyperkalemia. Stress-dose glucocorticoids (e.g., intramuscular hydrocortisone 50–100 mg/m² during acute illness, trauma, or surgery) must be prescribed and patient/caregiver education on sick-day rules is critical to prevent adrenal crisis. Emerging adjunctive therapies under investigation include CRH antagonists, androgen receptor blockers (e.g., spironolactone, flutamide), and aromatase inhibitors for fertility preservation—but none are standard-of-care outside clinical trials.

Surgical intervention is reserved for specific indications and is not curative. Genitoplasty is considered in virilized 46,XX females with Prader stage III–V genital ambiguity to improve urinary function, facilitate hygiene, and align external anatomy with gender identity. Timing remains individualized; current consensus favors delaying definitive surgery until the patient can participate meaningfully in decision-making—typically after age 16—unless urgent functional concerns exist. Clitoroplasty and vaginoplasty require expertise in pediatric urology/gynecology and lifelong follow-up for stenosis, scarring, or sexual dysfunction. Adrenalectomy is contraindicated in classic CAH due to absolute dependence on exogenous glucocorticoids and mineralocorticoids; however, unilateral adrenalectomy may rarely be performed for large, symptomatic adrenal myelolipomas or incidentalomas with atypical imaging features. Laparoscopic approaches are standard where available, minimizing morbidity.

Treatment advantages in China reflect rapid advancements in endocrine infrastructure and integration of precision medicine. Over 300 certified neonatal screening centers nationwide enable early detection of classic CAH, reducing mortality from salt-wasting crises. National guidelines (e.g., Chinese Endocrine Society CAH Consensus, 2022) standardize diagnostic algorithms, hydrocortisone dosing protocols, and long-term surveillance schedules. Access to generic hydrocortisone and fludrocortisone has improved markedly, with subsidized pricing under the National Reimbursement Drug List. Leading academic hospitals—including Peking Union Medical College Hospital, Shanghai Sixth People’s Hospital, and West China Hospital—offer multidisciplinary CAH clinics integrating endocrinology, genetics, pediatric surgery, psychology, and reproductive medicine. Advanced diagnostics such as next-generation sequencing for CYP21A2 mutation analysis, LC-MS/MS-based steroid profiling, and AI-assisted bone age assessment enhance phenotypic correlation and therapeutic personalization. Telemedicine platforms now support rural follow-up, mitigating geographic disparities in specialist access.

Recovery and long-term management emphasize adherence, self-efficacy, and holistic wellness. Patients and families must receive comprehensive education on medication timing, stress dosing, emergency injection techniques, and symptom recognition of adrenal insufficiency (e.g., fatigue, nausea, hypotension). Annual assessments should include auxology, bone densitometry (DXA) starting at age 18, oral glucose tolerance testing, lipid profile, blood pressure monitoring, and pelvic ultrasound in females with non-classic CAH to assess ovarian morphology. Adolescents transitioning to adult care require structured transfer programs to ensure continuity. Fertility counseling is vital: women with classic CAH often achieve pregnancy with optimized glucocorticoid regimens and assisted reproductive technologies; men may require sperm analysis and testosterone optimization. Psychosocial support—including peer networks, gender-affirming counseling, and mental health screening for anxiety/depression—is strongly recommended. Lifelong follow-up is non-negotiable: even well-controlled patients face elevated cardiovascular risk and require proactive preventive strategies. With rigorous, individualized, and compassionate care, individuals with CAH can expect near-normal life expectancy, quality of life, and reproductive outcomes.